Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Anaplastic lymphoma kinase (ALK) also known as ALK tyrosine kinase receptor or CD246, is an enzyme that in humans is encoded by the ALK gene. ALK is a membrane associated tyrosine kinase receptor of the insulin receptor superfamily. The function of the full-length ALK receptor is poorly understood. It has a probable role in the central and peripheral nervous system development and maintenance. ALK is a dependence receptor, which may exert antagonist functions, proapoptotic or antiapoptotic, depending on the absence or presence of a ligand. Dependence receptors have a potential role in cancer and development. The EML4-ALK fusion gene is responsible for approximately 3-5% of non-small-cell lung cancer(NSCLC) and this gene product was designed for the treatment of NSCLC.
Associated Disease
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| CAR-LC101 | Anti-ALK (ALK15) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | ALK15 | Mouse | scFv-CD28-CD3ζ | Retroviral | T cell | ||
| CAR-LC102 | Anti-ALK (ALK15) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | ALK15 | Mouse | scFv-41BB-CD3ζ | Retroviral | T cell | ||
| CAR-LC103 | Anti-ALK (ALK15) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 | Human | ALK15 | Mouse | scFv-CD28-41BB-CD3ζ | Retroviral | T cell | ||
| CAR-LC104 | Anti-ALK (hALK15SH) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | hALK15SH | Human | scFv-CD28-CD3ζ | Retroviral | T cell | ||
| CAR-LC105 | Anti-ALK (hALK15SH) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | hALK15SH | Human | scFv-41BB-CD3ζ | Retroviral | T cell | ||
| CAR-LC106 | Anti-ALK (hALK15SH) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 | Human | hALK15SH | Human | scFv-CD28-41BB-CD3ζ | Retroviral | T cell | ||
| CAR-LC107 | Anti-ALK (ALK48) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | ALK48 | Mouse | scFv-CD28-CD3ζ | Retroviral | T cell | ||
| CAR-LC108 | Anti-ALK (ALK48) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | ALK48 | Mouse | scFv-41BB-CD3ζ | Retroviral | T cell | ||
| CAR-LC109 | Anti-ALK (ALK48) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 | Human | ALK48 | Mouse | scFv-CD28-41BB-CD3ζ | Retroviral | T cell | ||
| CAR-LC110 | Anti-ALK (hALK48SH) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | hALK48SH | Human | scFv-CD28-CD3ζ | Retroviral | T cell | ||
| CAR-LC111 | Anti-ALK (hALK48SH) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | hALK48SH | Human | scFv-41BB-CD3ζ | Retroviral | T cell | ||
| CAR-LC112 | Anti-ALK (hALK48SH) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 | Human | hALK48SH | Human | scFv-CD28-41BB-CD3ζ | Retroviral | T cell | ||
| CAR-LC113 | Anti-ALK (ALK53) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | ALK53 | Mouse | scFv-CD28-CD3ζ | Retroviral | T cell | ||
| CAR-LC114 | Anti-ALK (ALK53) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | ALK53 | Mouse | scFv-41BB-CD3ζ | Retroviral | T cell | ||
| CAR-LC115 | Anti-ALK (ALK53) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 | Human | ALK53 | Mouse | scFv-CD28-41BB-CD3ζ | Retroviral | T cell | ||
| CAR-LC116 | Anti-ALK (hALK53) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | hALK53 | Human | scFv-CD28-CD3ζ | Retroviral | T cell | ||
| CAR-LC117 | Anti-ALK (hALK53) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | hALK53 | Human | scFv-41BB-CD3ζ | Retroviral | T cell | ||
| CAR-LC118 | Anti-ALK (hALK53) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 | Human | hALK53 | Human | scFv-CD28-41BB-CD3ζ | Retroviral | T cell | ||
| CAR-LC119 | Anti-ALK (ALK58) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | ALK58 | Mouse | scFv-CD28-CD3ζ | Retroviral | T cell | ||
| CAR-LC120 | Anti-ALK (ALK58) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | ALK58 | Mouse | scFv-41BB-CD3ζ | Retroviral | T cell |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
